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Abstract: Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein expressed in
epithelial tissues. EpCAM forms intercellular, homophilic adhesions, modulates epithelial junctional
protein complex formation, and promotes epithelial tissue homeostasis. EpCAM is a target of
molecular therapies and plays a prominent role in tumor biology. In this review, we focus on
the dynamic regulation of EpCAM expression during epithelial-to-mesenchymal transition (EMT)
and the functional implications of EpCAM expression on the regulation of EMT. EpCAM is frequently
and highly expressed in epithelial cancers, while silenced in mesenchymal cancers. During EMT,
EpCAM expression is downregulated by extracellular signal-regulated kinases (ERK) and EMT
transcription factors, as well as by regulated intramembrane proteolysis (RIP). The functional impact
of EpCAM expression on tumor biology is frequently dependent on the cancer type and predominant
oncogenic signaling pathways, suggesting that the role of EpCAM in tumor biology and EMT is
multifunctional. Membrane EpCAM is cleaved in cancers and its intracellular domain (EpICD) is
transported into the nucleus and binds β-catenin, FHL2, and LEF1. This stimulates gene transcription
that promotes growth, cancer stem cell properties, and EMT. EpCAM is also regulated by epidermal
growth factor receptor (EGFR) signaling and the EpCAM ectoderm (EpEX) is an EGFR ligand that
affects EMT. EpCAM is expressed on circulating tumor and cancer stem cells undergoing EMT and
modulates metastases and cancer treatment responses. Future research exploring EpCAM’s role in
EMT may reveal additional therapeutic opportunities.
Keywords: epithelial cell adhesion molecule (EpCAM); epithelial cancers; epithelial-to-mesenchymal
transition (EMT); metastasis; circulating tumor cells (CTCs); cancer stem cells (CSCs)
1. Introduction
Epithelial cell adhesion molecule (EpCAM) is an approximately 40 kilodalton (kD),
type I transmembrane glycoprotein. The human EPCAM gene is located on chromosome
2 (2p21) and has an estimated size of 14 kilobases (kb) [1]. EpCAM is expressed on
the basolateral membrane of most epithelial tissues and the highest expression levels are
observed in colonocytes. Limited expression is observed in some epithelial types (e.g.,
squamous cells of the skin and hepatocytes) and mesenchymal cells, including nervous,
connective, and bone-marrow-derived cells [2,3]. EpCAM plays a prominent role in
forming intercellular adhesions, maintaining the epithelial integrity of the gastrointestinal
tract, and promoting the epithelial phenotype across various tissue types.
Embryological studies demonstrate that EpCAM plays an important role in epithe-
lial organ development and placental formation [4]. Germline EpCAM mutations cause
congenital tufting enteropathy (CTE), a chronic diarrheal illness that typically presents in
neonates and causes intractable diarrhea and intestinal failure [5]. Mutations associated
with CTE prevent surface expression of EpCAM [6], which in turn causes villous atrophy,
the formation of epithelial tufts [7], and the aberrant expression of cellular adhesion pro-
teins including integrins, desmogleins, E-cadherin, β-catenin, claudin-7, occludin, and
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zona occludens-1 [8–11]. This results in intestinal barrier and ion transport dysfunction
and diarrheal illness [10,11]. In addition to its adhesive role, EpCAM can also function as
a signaling molecule. Upon cleavage of full length EpCAM at the cell membrane, EpCAM’s
intracellular domain (EpICD) serves as a nuclear signaling molecule along with β-catenin
and regulates the transcription of target genes [12]. EpCAM’s extracellular domain (EpEX)
can also be cleaved and secreted, and recent studies have shown it can serve as a ligand
for the epidermal growth factor receptor (EGFR). EpCAM’s precise role in EGFR signaling
remains to be fully clarified [13].
In addition to its role in healthy tissues, EpCAM plays a prominent role in cancer biol-
ogy and was the first human tumor-associated antigen to be identified using monoclonal
antibodies [14]. Subsequent studies have shown that EpCAM is frequently and strongly
expressed on the cell surface of many epithelial cancer types, with the highest expression
levels observed in adenocarcinomas of the pancreas, colon, and prostate [15]. Due to its
high antigenicity and expression, EpCAM has been a target of monoclonal antibody thera-
pies in colorectal cancer [16,17]. More recently, the trifunctional antibody Catumaxomab,
which targets EpCAM on epithelial cells and mitigates a multipronged, anti-cancer immune
response [18], has been used in the treatment of malignant ascites in epithelial cancers.
Clinical trials have demonstrated promising results [19–21] and Catumaxomab has been
approved for the intraperitoneal treatment of patients with malignant ascites in Europe [18].
EpCAM is also frequently the target of methods to capture and measure circulating tu-
mor cells (CTCs) in epithelial cancer patients [22], which provides important prognostic
information and can help to determine the response to therapeutic interventions.
During the last three decades, an expanding body of research has demonstrated that
EpCAM has many versatile functions that have important implications for cancer initiation,
progression, and the underlining mechanisms of epithelial-to-mesenchymal transition
(EMT). EMT is a differentiation program typically observed in higher order species, includ-
ing vertebrates, that allows epithelialized cells to differentiate into mesenchymal cells. EMT
enables cell migration in the developing embryo and is essential for organogenesis and
tissue regeneration [23]. In cancer, EMT is a complex process in which epithelial cancer cells
alter key characteristics and assume a mesenchymal phenotype that enables cell motility,
invasion, and metastasis. Broadly speaking, there are several hallmark modifications that
occur during EMT. First, epithelial cells deconstruct their intercellular junctions, including
tight junctions, adherens junctions, desmosomes, and gap junctions. In turn, epithelial cells
lose their apical-basal polarity and acquire a front-rear organization. Second, cytoskeleton
actin is reorganized to form actin stress fibers and cellular extensions, including lamel-
lipodia, filopodia, and invadopodia, which enables directional migration. Finally, cells
gain the ability to degrade extracellular matrix (ECM) proteins, which promotes invasive
behavior. These changes are mediated by complex signaling cascades and transcription
factor activity [24].
During many of the aforementioned processes, EpCAM is increasingly being demon-
strated to play an important role in EMT. EpCAM is typically downregulated during EMT
in epithelial cancers. This is mediated by extracellular signal-regulated kinases (ERK), EMT
transcription factor activity, and other oncogenic mechanisms and pathways. During EMT,
EpCAM can also be cleaved during a process called regulated intramembrane proteolysis
(RIP) and its intracellular domain (EpICD) is transported into the nucleus and helps to
stimulate target gene transcription that promotes growth, cancer stem cell properties, and
EMT. EpCAM also appears to have a functional impact on EMT. Given the multifunctional
role of EpCAM, modulation of EpCAM expression can have differential outcomes on tumor
biology and EMT and EpCAM can either inhibit or promote EMT. These observations are
typically context dependent and are based on the cancer type that is being analyzed. As
discussed below, EpCAM typically promotes malignant properties in epithelial cancers, but
can have an inhibitory or negligible impact in mesenchymal cancers. In addition, EpCAM’s
different protein domains have unique roles in EMT and their function is also dependent
on the cellular and/or extracellular location of their expression. In some studies, it is not
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clear which domain of EpCAM is causing the observed effect on EMT. Our expanding
knowledge of EpCAM’s role in EMT has provided important pathological markers for
cancer patients and is revealing potential therapeutic opportunities.
2. EpCAM Forms Intercellular Adhesions and Promotes Cellular Segregation
and Aggregation
EpCAM is a unique cell adhesion molecule (CAM) that does not resemble other
classical adhesion molecules (e.g., cadherins, selectins, integrins, and immunoglobulin-
like-CAMs) in either structure or function. EpCAM’s protein structure (Figure 1) is highly
conserved across different species, especially in higher vertebrates including humans [1].
EpCAM consists of a large extracellular component (242 amino acids) with a smaller
single-pass transmembrane (23 amino acids) and an intracellular (26 amino acids) structure.
EpCAM has 314 amino acids and six described domains: signal peptide (SP), N-terminal
domain (ND), type-1 thyroglobulin domain (TY-1), carboxyl-terminal domain (CD), trans-
membrane domain (TM), and intracellular domain (EpICD). Recent structural studies
demonstrate that EpCAM’s extracellular tertiary structure assumes a heart, or triangle
shape and EpCAM frequently forms cis dimers on epithelial cell surfaces [25,26].
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Early functional studies demonstrated that EpCAM forms physical interactions be-
tween cells, functions as a cell adhesion molecule, and causes cell aggregation. In a seminal
study published in 1994, Litvin v et al. force-expressed EpCAM in murine fibroblast and
breast cancer cell lines and demonstrated that E CAM forms homophilic, intercellular adhe-
sions. This in turn cause c ll aggregation nd cell sorting/segregation from non-EpCAM
expressing cells. U like other cl ssical CAMs (e.g., cadherins), this occurred in a calcium
inde ende t manner, which is a unique feature of EpCAM. It is al o important to note
that the adh sions formed by EpCAM were weaker than those formed by E-cadherin [27].
These findings were also sup orted by experiments i human tissues and human breast
and ovaria cancer ce l lines. EpCAM was shown to localize predominantly along the lat-
eral membrane at points of contact in polarized cells, but did not appear to interact with
xtrac llular matrix proteins i clud g fibron ctin, collagens, and laminin. A n utralizing
antibody that t rgeted the extracellular domain of EpCAM was able to abrogate EpCAM’s
adhesive properties [28]. Using immunofluorescent and electron microscopy techniques,
EpCAM was als shown to form i tercellular adhesion structures in the proximity of, but
separate from, cadherins. EpCAM was not present near tight junctions or desmos mes [29].
It was further demonstrated that EpCAM’s ability to form intercellular adhesions and affect
cellular aggregation was dependent on EpCAM’s binding of α-actin by its cytoplasmic tail.
Cytoplasmic tail mutations reduced EpCAM’s localization to the cell surface and decreased
EpCAM’s aggregative abilities [30].
Other studies have elucidated the structural organization of intercellular adhesions
formed by EpCAM. Chemical crosslinking and EpCAM crystal structure studies demon-
strated that EpCAM cis dimers likely align in a head-to-head orientation and form a rhombo-
hedral-shaped trans-tetramer that mediates cell adhesions [25,31]. Balzar et al. proposed
a different model with the formation of trans octamers from cis tetramers. They also demon-
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strated that EpCAM mutations in the extracellular domain and EpCAM antibodies could
abrogate both trans-cellular and cis-cellular interactions between EpCAM proteins [32].
Some studies demonstrate, however, that EpCAM may not form intercellular adhe-
sions. Gaber et al. recently reported their findings of multiple experimental assays that
did not demonstrate EpCAM forming intercellular adhesions. EpEX oligomer formation in
solution was analyzed using small angle X-ray scattering (SAXS) and tetramers that would
form intercellular adhesions were not detected. Chemical cross-linking coupled with mass
spectroscopy identified the position of EpCAM oligomer interactions. However, based on
a detailed computational analysis, the detected interactions were not predicted to support
the formation of trans tetrameric adhesion units. The investigators also determined that Ep-
CAM cis dimers did not form trans interactions using bead aggregation assays (BAA) and
fluorescence-lifetime imaging based Förster resonance energy transfer (FILM-FRET) [26].
Fagotto et al. recently provided a critical review of earlier experimental data and ques-
tioned EpCAM’s ability to affect transcellular adhesions. In particular, the authors noted
that the small and sparsely disbursed EpCAM adhesions identified by electron microscopy
would not be capable of causing the broad and close approximation of the cell membrane
that was being observed [33]. While these two reports provide important evidence and
critical questions, further investigation is needed for clarification. Most studies, however,
show that EpCAM is a CAM that forms homophilic, intercellular adhesions, maintains
epithelial integrity, and promotes cellular aggregation.
3. Transcriptional Control of EpCAM Expression and its Downregulation during EMT
As previously mentioned, EpCAM is expressed in epithelial organs, while limited
expression is observed in mesenchymal tissues [2,3]. A similar pattern has been extensively
characterized in epithelial and mesenchymal cancers [34] and will be discussed in greater
detail below. In a comprehensive analysis, EpCAM gene silencing was identified to
be part of a 76 gene signature of EMT [35]. EpCAM expression is highly regulated by
transcriptional control mechanisms (Figure 2). Many different signaling proteins and
transcription factors, including those that have prominent roles in cancer initiation and
progression and EMT, have been shown to either directly or indirectly silence EpCAM
promoter activity and expression during EMT.
In an important study, Sankpal et al. demonstrated that EpCAM is dynamically
regulated during EMT in a novel double-negative feedback loop in epithelial cancers.
Double-negative feedback loops promote bi-stable states, whereby the products of one
state (e.g., proteins) prevent the activation of the alternative state and vice versa. Double-
negative feedback loops are frequently observed in biological systems [36]. In silico
and in vitro analysis demonstrated that EpCAM silencing is associated with increased
ERK pathway activation, which is a potent mediator of EMT. ERK2 was shown to bind
the EpCAM promoter at an ERK2-binding consensus sequence and directly inhibit EpCAM
gene transcription. ERK2 also induced EMT transcription factor activity (SNAI1, SNAI2,
and TWIST1), which in turn also inhibited EpCAM gene transcription. Surprisingly,
EpCAM was able to inhibit ERK signaling and ERK gene targets in EMT, including SNAI2,
EGR1, FOS, JUN, ATF3, and others in MCF-10A breast epithelial cells, thus forming
a double-negative feedback loop [37]. The precise mechanism by which EpCAM inhibits
ERK activity remains to be clarified. In contrast, in a mouse model of liver fibrosis, increased
ERK activation was associated with cell proliferation and EpCAM overexpression, though
it was not specifically tested if ERK activation caused EpCAM overexpression [38]. Thus,
the role of ERK signaling on EpCAM expression may also be dependent on the tissue type.
ZEB1 is an E-box transcriptional repressor that induces EMT. In lung, breast, and
pancreatic cancers, ZEB1 was shown to either directly or indirectly inhibit transcription
of EpCAM. This was facilitated by ZEB1 binding of the EpCAM promoter and by ZEB1
induced changes in histone acetylation levels [39–41]. Similarly, EMT transcription factors
SNAI1, SNAI2, and TWIST1 have been shown to negatively regulate EpCAM transcription
in epithelial cancers [37]. In a study examining EpCAM’s regulation in ovarian cancer
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cell lines, van der Gun et al. identified multiple mechanisms that modulated EpCAM
expression, including transcription factor signaling [42]. Several of these transcription
factors, including ETS1, LEF1, NF-κβ, SP1, and STAT3, have been implicated in promot-
ing EMT [43–47], though their exact impact on EpCAM gene expression remains to be
fully clarified. Wnt-β-catenin signaling, which is frequently upregulated in cancer and
promotes EMT [48], can stimulate EpCAM expression. Yamashita et al. demonstrated that
a transcription factor 4 (TCF4)/β-catenin protein complex binds Tcf binding elements in
the EpCAM promoter and promotes EpCAM expression and in vitro growth in hepatocyte
and hepatocarcinoma cell lines [49].
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ing silences EpCAM expression. ERK2 binds the EpCAM promoter at an ERK2-binding consensus
sequence and directly inhibits EpCAM gene expression. ERK2 also induces EMT transcription factors,
including SNAI2, that in turn also inhibit EpCAM transcription.
Additional studies have shown that epigenetics changes are an important regulator
of EpCAM expression. In ovarian cancer, gene promoter methylation and histone mod-
ifications were associated with EpCAM expression patterns [42]. Similar results were
also demonstrated in oral squamous cell and colon cancers [50,51]. Sankpal et al. demon-
strated that p53, which is frequently mutated and inactivated in cancer, binds the EpCAM
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promoter at p53 candidate binding sites and represses transcription in breast cancer cell
lines [52]. Wildtype p53 also silenced EpCAM expression by inducing gene methylation
changes [53]. In liver cancer, histone lysine demethylase 4D (JMJD2D) reduced histone
methylation levels and increased EpCAM and cancer stem marker SOX9 expression [54].
The precise role epigenetic changes play in modulating EpCAM expression during EMT
remains to be clarified.
4. Regulated Intramembrane Proteolysis of EpCAM and EpICD Signaling
during EMT
In 2009, it was shown that EpCAM can function as an intracellular signaling molecule
and this likely plays an important role in EMT (Figure 3). EpCAM is cleaved at the cel-
lular membrane in a process called regulated intramembrane proteolysis (RIP) by tumor
necrosis factor-α-converting enzyme (TACE, also known as ADAM metallopeptidase
17 [ADAM17]) and presenilin 2 (PSEN2), which is part of the γ-secretase complex. This
cleavage is stimulated by soluble EpEX binding of EpCAM, cell–cell contact, and EGFR sig-
naling [12,55,56]. The role of EGFR signaling is discussed in further detail below. EpCAM
cleavage releases the intracellular domain of EpCAM (EpICD) into the cytoplasm where
it is transported into the nucleus. Nuclear EpICD binds Four-and-a-half LIM Domains
2 (FHL2), Lymphoid Enhancer Binder Factor 1 (LEF1), and β-catenin to form a DNA bind-
ing complex that stimulates the transcription of target genes. This in turn promotes tumor
growth and EMT [12,44,55–58]. Upregulated nuclear β-catenin signaling is a major driver
in many cancers and promotes EMT [48]. These findings suggest that RIP of EpCAM,
which would presumably relieve its adhesive function, also likely promotes EMT. A recent
study demonstrated that RIP and EpICD generation occurs rather slowly compared to other
signaling mechanisms. The authors of this study concluded that EpICD generation by RIP
is responsible for steady signaling events, as opposed to rapid transmission of extracellular
cues into de novo gene transcription [59]. This would suggest that EpICD signaling may
not be an initiating or driver event in EMT, but rather may play a supporting role.
In addition to its signaling role, β-catenin also binds E-cadherin at the cell surface and
participates in the formation of cell adhesions. By a series of complex phosphorylation
and other events, β-catenin is released from cadherins to participate in down-stream
signaling [60]. Whether EpCAM directly causes the release of β-catenin from E-cadherin
is unknown, but it has been shown that silencing of EpCAM in breast cancer cell lines
increased β-catenin binding to the cytoskeleton [61]. Thus, by its effect through nuclear
signaling (EpICD) and its negative regulation of E-cadherin (discussed below), EpCAM
may be able to regulate β-catenin signaling and EMT progression through two separate
mechanisms, though further research is needed. Interestingly, other studies have also
shown that increased β-catenin signaling also stimulates EpCAM expression. β-catenin
formed a complex with TCF4, and Tcf elements in the EpCAM promoter could bind
TCF4, which in turn stimulated EpCAM gene expression [49]. Shi et al. demonstrated
that cytokeratin 18 (CK18) silencing in breast cancer cells, which is observed during
EMT, promoted β-catenin signaling and increased expression of EpCAM [62]. Similarly,
in an in vitro and in vivo analysis of triple negative breast cancers (TNBC), reversal of
EMT progression by DNA methyltransferase and histone deacetylase inhibitor treatment,
decreased EpCAM cleavage and nuclear signaling with TCF4 [63].
Analysis of human tumor samples has shown that increased nuclear expression of
EpICD is associated with aggressive cancer behavior, which is consistent with EpICD’s
possible role in promoting EMT through β-catenin signaling. Nuclear expression of EpICD
is a marker of more aggressive behavior in oral squamous cell carcinoma [64], thyroid can-
cer [65], breast cancer [66], cholangiocarcinoma [67], and pancreatic adenocarcinoma [68].
A comprehensive study that looked at ten epithelial cancer types demonstrated that cy-
toplasmic and nuclear expression of EpICD is frequently observed in cancers, but not
typically observed in normal tissues. In some cancer types, membranous EpCAM expres-
sion is lost, while increased cytoplasmic and nuclear expression is present, suggesting that
RIP of EpCAM has occurred [69]. In some studies, however, nuclear expression of EpICD
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represented a favorable prognostic marker [70], highlighting the context dependent role of
EpCAM in tumorigenesis and EMT.
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of E-cadherin. This may free β-catenin for downstream signaling with EpICD.
In summary, these studies dem nstrate hat EpCAM is regul ted by in ricate feedback
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5. EpCAM Is Regulated by EGFR Signaling during EMT and EpEX Is an EGFR Ligand
that Affects EMT
EpCAM and EMT have been shown to be regulated by EGFR signaling (Figure 3).
Analysis in endometrial and colon cancer cell lines demonstrated that EGF treatment
caused EpCAM cleavage by γ-secretase. In turn, EpICD, together with LEF1, promoted
transcription of genes involved in EMT, including those that play a key role in junctional
protein complex formation and cell migration. EGF treatment also caused increased
softness, decreased adhesiveness, and increased invasion, phenotype changes consistent
with EMT [44,56,71].
Several groups have shown that the extracellular domain of EpCAM (EpEX) can
also serve as an EGFR ligand. Pan et al. demonstrated that EpEX binds EGFR in head
and neck cancer cell lines. Unlike the findings observed in endometrial cancers, EGF
treatment had minimal effects on RIP of EpCAM. Rather, EpEX functioned as a competitive
EGFR ligand. Co-stimulation of EGF with EpEX blunted the effects of EGF induced EMT
phenotype changes and expression of EMT transcription factors (SNAI1 SNAI2, and ZEB1).
EpEX’s proliferative effects on EGFR stimulation was modulated by ERK activity [13]. In
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colon cancer, EpEX stimulation of EGFR promoted proliferation, migration, and stemness
characteristics. This occurred via ERK signaling as well. An EpEX-EGFR-ERK signaling axis
also promoted RIP and EpICD nuclear translocation. Increased nuclear EpICD expression
in colon cancer specimens was associated with a worse prognosis [56,58].
Recently, EpEX-EGFR signaling was shown to promote PD-L1 expression in colon
and lung cancer cell lines. This suggests that EpEX may play a significant role in cancer
cell evasion of the host immunity [72], which is frequently observed with EMT [73]. In
an in vitro analysis of bone marrow derived mesenchymal stem cells, EpEX treatment
stimulated elaboration of stemness markers, and this occurred, in part, through EGFR
signaling [74]. Together, these studies demonstrate that EpEX can negatively or positively
regulate EMT through EGFR signaling. EpEX-EGFR-ERK signaling can also induce RIP of
EpCAM and release of EpEX, suggesting the presence of a possible positive feedback loop
involving EGFR.
6. EpCAM Mediates Migration and Invasion through Various Signaling Pathways
and Mechanisms
While EpCAM has typically been shown to be downregulated with EMT, EpCAM
can promote invasion in epithelial cancers, a phenotype typically acquired with EMT.
Multiple oncogenic pathways and cellular mechanisms have been associated with this
role. Notable reports are listed in Table 1, and are reviewed here. In some of these studies,
the precise mechanism by which EpCAM stimulates invasion is not clearly delineated. For
a comprehensive analysis, please refer to the review by Fagotto et al. [33].
Table 1. EpCAM is associated with migration and invasion modulation via various signaling pathways and mechanisms.
Cell Type & Cell Line Associated SignalingPathway/Mechanism Promotes/Inhibits Reference
Head and Neck Squamous Cell Carcinoma: FaDu and
Kyse-30 EpEX & EGFR Inhibits [13]
Nasopharyngea S Carcinoma: S18, 6-10B, and HONE1 PTEN/AKT/mTOR Promotes [75]
Esophageal Squmous Cell Carinoma: Kyse-30 and
Kyse-520 EMT Inhibits [76]
Lung Cancer: A549 and NCI-H446 MTA1 Promotes [77]
Benign Breast: MCF-10A and Human Mammary
Epithelial Cells ERK & EMT Inhibits [37,78]
Breast Cancer: MDA-MB-231 E-Cadherin & α,β-catenin Promotes [61]
Breast Cancer: MDA-231 and CA1a AP-1 Promotes [79]
Breast Cancer: MCF-7 TGF-β1 Promotes [80]
Breast Cancer: MDA-MB-231 NF-κβ Promotes [81,82]
Breast Cancer: MCF-7, T47D, SkBR3, MDA-MB-231, and
Hs578t EMT Both [83]
Kideny: MDCK ERK, Claudin-7, &actomyosin contractility Inhibits [84]
Colon: HCT116 EpEX & EpICD Promotes [55]
Endometrial: Ishikawa and RL95-2 Adhesion formation & EpICD Both [44]
Ovarian: SKOV3 & OVCAR4 ERK Inhibits [85]
Prostate: KrasG12D & p53L/L mouse knockout prostate
cancer model
KRAS & p53 Promotes [86]
Langerhans cells: Knockout mice model Decrease adhesiveness Promotes [87]
Embryonic and Colon: Xenopus laevis and Caco-2 and
SW480 nPKC and myosin regulation Promotes [88,89]
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In breast cancer, multiple studies suggest that EpCAM promotes invasion. In one
of the first studies to characterize this phenomenon, EpCAM knockdown in MDA-MB-
231 cells was shown to modulate cadherin and catenin binding to the cytoskeleton and
inhibit migration and invasion [61]. The transcription factor activator protein 1 (AP-1)
plays a central role in promoting cancer cell metastases and coordinating the activation
and silencing of genes involved in cancer invasion. AP-1 is a dimeric protein complex
consisting of Fos and Jun members [90]. EpCAM was shown to stimulate AP-1 transcription
factor activity in breast cancer cell lines. EpCAM overexpression caused AP-1 activation
through c-Jun subunit phosphorylation and MEK1/MKK7/JNK transduction pathway
signaling. In turn, this modulated AP-1 target gene expression and promoted cancer cell
invasion [79]. TGF-β1 treatment induced EMT and migration in breast cancer cell line MCF-
7, and this was shown to be modulated through a JNK/AP-1/EpCAM signaling axis [80].
EpCAM has also been shown to modulate IL-8 and NF-κβ expression and invasion in
breast cancer cell lines [81]. EpCAM overexpression promoted EMT and expression of
stem cell markers (NANOG, SOX2, and OCT4) under hypoxic conditions in breast cancer
cell lines and this effect also occurred through NF-κβ signaling as well [82]. It is important
to note that EpCAM’s effect can be dependent on the cell type. In breast cancer cell
lines with an epithelial phenotype, EpCAM promoted invasion, while in cell lines with
a mesenchymal phenotype, EpCAM had minimal impact on invasion [83].
EpCAM has been shown to promote invasion in other cell types and cancers. In vivo
experiments in mice that expressed EpCAM-deficient Langerhans cells (LC) showed de-
creased LC migration. It was postulated this occurred because of EpCAM’s ability to
negatively regulate LC adhesions to keratinocytes, though specific functional data was lack-
ing [87]. In nasopharyngeal cancer, EpCAM was shown to promote EMT and metastasis
formation in vitro and in vivo, which was mediated by PTEN/AKT/mTOR signaling [75].
In lung cancer, increased EpCAM expression along with Metastasis-associated protein 1
(MTA1) promoted migration [77]. Oncogenic KRAS and p53 mutations in a prostate cancer
mouse model caused EpCAM overexpression, which was associated with increased inva-
sion and stemness characteristics [86]. Embryonic analysis also demonstrated that EpCAM
is a novel protein kinase C (nPKC) inhibitor and regulates myosin activity. The cytoplasmic
tail of EpCAM inhibited nPKC and EpCAM knockdown caused increased nPKC and ERK
activity, which resulted in aberrant myosin contractility and migration [88,89]. EpCAM’s
regulation of myosin activity and cell adhesions (discussed in greater detail below) and
EpCAM’s signaling through EpICD (discussed above) provides a mechanistic explanation
for EpCAM’s ability to modulate and promote migration and invasion.
It is also important to note that other studies have shown that EpCAM negatively
affects migration and invasion or is downregulated with migration and invasion. This neg-
ative role was usually mitigated through EGFR and ERK signaling and was also typically
observed in mesenchymal cell types of multiple different cancer types [13,37,44,76,78,84,85].
This is consistent with previous findings demonstrating that EpCAM negatively regulates
ERK and EMT in a double-negative feedback loop [37].
7. EpCAM Regulates the Formation of Epithelial Junctional Protein Complexes and
May Affect EMT
In addition to its homophilic adhesive properties, EpCAM has been shown to modu-
late other junctional protein complexes (e.g., cadherins and tight junctions) that are impor-
tant for maintaining epithelial integrity and are modulated during EMT [24]. EpCAM’s
impact on cadherins and tight junctions provides one possible mechanistic explanation
for EpCAM’s pro-invasive effect, though further research is needed. E-cadherin and
N-cadherin play essential roles in EMT. During EMT, epithelial cells replace E-cadherin
expression with N-cadherin expression. This causes transitioning cells to acquire a mes-
enchymal phenotype and promotes cell migration and invasion [91,92]. Inducible over-
expression of EpCAM was shown in E-cadherin and N-cadherin expressing cell lines to
reduce aggregation caused by both cadherin types. Moreover, forced EpCAM overexpres-
sion redistributed N-cadherins from cadherin junctions to diffuse points along the cell
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membrane. This negative effect on cadherin adhesion activity was also associated with
decreased cadherin binding of α-catenin and β-catenin, which are important linkers be-
tween cadherins and the cytoskeleton [93]. While EpCAM was shown to negatively affect
both E- and N-cadherin, it is important to note that EpCAM is frequently expressed at high
levels in epithelial cancers that predominantly express E-cadherin. A follow-up analysis by
the same group demonstrated that EpCAM decreased E-cadherin’s intercellular adhesion
strength, in part, by disrupting the binding of E-cadherin to the cytoskeleton via α-catenin
and possibly through pp120 interaction as well. Interestingly, EpCAM overexpression
also caused formation of actin stress fibers, which is observed during EMT [94]. In breast
cancer, EpCAM is highly overexpressed in primary and metastatic lesions. Silencing of
EpCAM in vitro increased cytoskeleton associated expression of E-cadherin, α-catenin,
and β-catenin and decreased cell proliferation, migration, and invasion in MDA-MB-231
cells [61]. In contrast, embryological analysis in zebrafish demonstrated that EpCAM
worked cooperatively with E-cadherin. Mutant EpCAM was associated with decreased
E-cadherin expression [95].
EpCAM has also been shown to bind claudins and affect tight junction formation.
Tight junctions are important for maintaining normal epithelial integrity at apical mem-
branes and loss of tight junctions is associated with EMT and tumorigenesis in multiple
cancer types including brain [96], breast [97], and pancreas [98] cancers. Ladwein et al.
showed that EpCAM binds claudin-7 in rat and human pancreas cancer cell lines and in
human tumor samples [99]. In similar studies, EpCAM was shown to bind claudin-7 and
claudin-1 in human colorectal cell lines and silencing of EpCAM increased tight junction
formation. Furthermore, EpCAM was upregulated in human colorectal cancers and formed
a complex with claudin-7 in primary tumors and metastases. This complex formation was
associated with chemotherapy resistance and decreased survival [100,101]. In HEK293
and rat pancreatic cancer cell lines, EpCAM and claudin-7 were shown to form a complex
which promoted migration and tumor growth, and this was associated with increased
ERK signaling. Binding of claudin-7 occurred through the TM domain of EpCAM, and
also prevented EpCAM oligomerization [102]. Interestingly, it was also demonstrated that
claudin-7 associated TACE and PSEN2 cleaved EpCAM, which subsequently increased
EpICD signaling and expression of EMT transcription factors [103].
Together, these studies demonstrate that EpCAM modulates junctional protein com-
plex formation and function and regulates epithelial adhesions formed by cadherins and
claudins. Claudins can also affect RIP and EpICD signaling. While EpCAM itself can form
homophilic adhesions (albeit weaker than E-cadherin), its effect can also possibly reduce
overall adhesion strength by affecting other adhesion molecules. Loss of cellular adhesion
strength and commensurate relief of contact inhibition is a major feature of EMT and cancer
initiation [24,104]. In cancer, this may be controlled somewhat paradoxically by EpCAM’s
selective and relatively weak aggregative abilities in conjunction with its negative effects on
cadherin and tight junction formation. That said, it remains to be determined if EpCAM’s
effect on cadherins and claudins drives EMT.
8. EpCAM Expression in Epithelial and Mesenchymal Cancers
Analysis of EpCAM’s expression patterns in diverse cancer specimen types has pro-
vided important insights into EpCAM’s role in EMT. In general, tumors of mesenchymal
origin have low EpCAM expression, while cancers of epithelial origin have high EpCAM
expression. Accordingly, low EpCAM expression was observed in melanoma, some neu-
rological cancers, lymphomas, and sarcomas [15], while high EpCAM expression was
observed in breast [61], gallbladder [105], gastric [106], pancreatic [107], prostate [108,109],
and colorectal cancers [110]. Some epithelial cancers, however, demonstrated low EpCAM
expression, including squamous cell cancers, hepatocellular carcinomas, clear cell renal car-
cinoma, and urothelial cancers [111], while some sarcomas have shown elevated EpCAM
expression [112]. EpCAM expression is a negative prognostic marker in most epithelial
cancers, though exceptions are noted. For a comprehensive analysis of EpCAM’s prog-
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nostic significance in cancer, please refer to the review by van der Gun et al. [34]. EpICD
participates in nuclear signaling and has a critical role in regulating EMT (discussed above).
It is important to note that many studies do not clearly distinguish the cellular location of
EpCAM expression in these analyses (e.g., membranous, cytoplasmic, or nuclear).
In a comprehensive study that examined EpCAM expression in primary and solid
metastatic lesions, high EpCAM expression was frequently present in metastases of ep-
ithelial cancers. The expression patterns in the metastases generally mirrored the expres-
sion patterns in the primary tumor, indicating that EpCAM expression is important for
metastatic development in epithelial cancers [111]. Indeed, in breast and prostate cancers,
higher EpCAM expression has been observed in metastatic lesions compared to the primary
tumors [109,113].
In some epithelial cancers, EpCAM expression varies within tumor subtypes and
representative examples are discussed here. EpCAM is frequently overexpressed in ductal
and metastatic breast cancers and high EpCAM expression can serve as a poor prognostic
marker [61,114–116]. Lobular and other histological breast cancer subtypes, however,
usually have lower EpCAM expression [111,115,116]. Pathological changes associated with
EMT have not usually been observed in lobular breast cancer [117] and it remains uncertain
what is the cause of lower EpCAM expression in this breast cancer subtype. Triple negative
breast cancer (TNBC) is an aggressive form of breast cancer that expresses a mesenchymal
phenotype [118], but also retains EpCAM expression. Indeed, a recent analysis of TNBC
specimens demonstrated that EpCAM and EMT markers were frequently co-expressed
and this expression pattern was associated with lymph node metastases and decreased
survival [119]. Similar results were also shown by Soysal et al. in their analysis of basal-like
breast cancer [116].
Well differentiated thyroid cancer, including papillary and follicular thyroid can-
cer, has high EpCAM expression. EpCAM expression is progressively lost with tumor
dedifferentiation in poorly differentiated (PDTC) and anaplastic thyroid (ATC) cancers.
Interestingly, membranous EpEX expression was associated with improved survival, while
nuclear EpICD expression was associated with decreased survival [65,120]. PDTC and ATC
have high expression of EMT markers and EMT is an important driver in thyroid cancer
dedifferentiation and progression [121,122]. This suggests that loss of EpCAM expression
in aggressive thyroid cancers is related to EMT.
Together, these tissue studies demonstrate that EpCAM promotes tumorigenesis in
epithelial cancers, but likely has a minimal role in mesenchymal cancers. Indeed, in
a comprehensive analysis that examined EMT gene expression signatures in 166 cancer cell
lines and in breast and lung cancers, EpCAM expression was significantly less or absent in
mesenchymal-like cancer cell lines and tumors [37].
9. EpCAM, Circulating Tumor Cells, and EMT
During the early steps of epithelial metastasis, cancer cells undergo EMT to detach
from the primary tumor, invade the surrounding tissues, and disseminate hematogenously
as circulating tumor cells (CTCs). CTCs are detectable in human blood samples of cancer
patients, generate metastases, and contribute to cancer progression. Detection of elevated
CTCs in clinical blood samples is typically associated with a worse prognosis and CTCs
levels and types can be monitored to determine the response to therapeutic interventions.
EpCAM is frequently used as a target to capture and measure CTCs [123–125]. As an ep-
ithelial marker, EpCAM has successfully been used in the CellSearch system [22] and others
to capture and measure CTCs. Detection of EpCAM positive CTCs has provided prog-
nostic information in breast [126], liver [127], prostate [128], colorectal cancer [129], and
neuroendocrine cancer patients [130]. These findings demonstrate that EpCAM supports
CTC propagation and the metastatic cascade in epithelial cancers.
Multiple studies demonstrate that EpCAM expression is retained in CTCs that are
affected by EMT. This is consistent with emerging evidence showing that cancer cells which
express an intermediary EMT phenotype may have increased metastatic potential [131].
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Liu et al. studied the effects of EpCAM and EMT in CTCs and DTCs in a mouse model
of metastatic breast cancer. Of the different types of CTCs identified, CTCs with a mod-
erate mesenchymal transition that retained EpCAM expression had greater metastatic
potential compared to CTCs with a prominent mesenchymal phenotype without EpCAM
expression [132]. Analogous results were also demonstrated in a mouse model of prostate
cancer [133]. EpCAM positive CTCs that co-express EMT markers were frequently detected
in breast and prostate cancer patients [134,135]. Similarly, detection of EpCAM positive
CTCs with high expression of EMT markers (ETV5, NOTCH1, SNAI1, TGFB1, ZEB1, and
ZEB2) was associated with a worse prognosis in endometrial cancer patients [136]. CTCs
that are isolated and cultured from epithelial cancer patients frequently retain EpCAM
expression, but also express mesenchymal markers [137–139]. Together, these results
demonstrate that CTCs expressing EpCAM and an intermediary mesenchymal phenotype
are an important driver of metastatic formation in epithelial cancers.
It has also been shown, however, that CTCs can undergo EMT and downregulate
EpCAM expression [140,141]. Indeed, in an important study, Yu et al. showed that breast
CTCs acquire an increasingly mesenchymal phenotype with treatment resistance and can-
cer progression [118]. Jojovic et al. showed in 1998 that newly formed, small metastatic foci
in a mouse model of colon cancer lacked EpCAM expression, while EpCAM expression
was observed in larger metastatic lesions. The authors reasoned that EpCAM expression
was silenced during the early stages of tumor cell dissemination and metastasis formation,
and that this was related to EMT [142]. Similar results were also shown in an analysis
of human cases of metastatic cancer by Rao et al. The authors demonstrated that the
expression of EpCAM on CTCs was approximately 10-times lower compared to primary
and metastatic lesions [143]. In esophageal cancer patients, EpCAM expression was lower
in lymph node and bone marrow disseminated tumor cells (DTCs). EpCAM silencing
by short-hairpin RNA (shRNA) in esophageal squamous cancer cell lines induced EMT
changes and promoted increased metastatic formation. Interestingly, EpCAM expression
was frequently reconstituted in the metastatic lesion formed by the shRNA EpCAM knock-
down clones [76]. Similar results were also observed in a mouse model of metastatic
prostate cancer using DU145 cells. Progressive rounds of metastatic formation in mouse
lymph nodes by DU145 cells initiated mesothelial-to-epithelial transition (MET) and in-
creased epithelial marker expression, including EpCAM [144]. These results show that
EpCAM is dynamically regulated during metastatic formation with changes in EpCAM
expression patterns during EMT and MET.
Accordingly, multiple studies have shown that loss of EpCAM expression with EMT
in CTCs is associated with increase metastatic potential and worse prognosis. Tachtsidis
et al. examined xenograft models of triple negative (using MDA-MB-468 cell line) and
ER-positive (patient derived) breast cancer and showed that low EpCAM and high EMT
marker expression in CTCs promoted tumor metastases [145]. Neoadjuvant and salvage
chemotherapy increased EpCAM negative, EMT positive CTCs in breast cancer patients,
suggesting that the loss of EpCAM expression in CTCs may enhance chemotherapy resis-
tance [118,146]. In pancreatic cancer, detection of CTCs with mesenchymal markers and
minimal EpCAM expression portended a worse prognosis and was associated with higher
stage tumors and metastatic disease [147]. Similar results were shown in an in vivo model
of hepatocellular carcinoma [148].
10. EpCAM, Cancer Stem Cells, and EMT
EpCAM and EpICD can also regulate and/or be controlled by reprogramming factors
involved in promoting tumor initiating cells (TICs), also known has cancer stem cells (CSC).
CSCs represent a subpopulation of tumor cells that have embryonic and mesenchymal
properties. CSCs supply a self-renewing source of cancer cells and promote cellular
dedifferentiation and tumor growth. It is believed that CSCs frequently form during EMT,
and CSCs share many of the same markers and phenotypic properties that characterize
EMT [149]. In normal human epithelial stem cells, EpCAM was shown to be expressed in
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OCT4 positive embryonic stem cells and EpCAM silencing had inhibitory effects on growth
and stemness characteristics [150]. In colon cancer, EpCAM served as a CSC marker and
was shown to be upregulated during signaling that promotes EMT [151,152]. Increased
EpCAM expression occurred with other CSC markers in chemotherapy resistant LoVo
colon cancer cells, which was mediated by CXC ligand signaling [153]. EpICD was shown
to stimulate the transcription of CSC reprogramming genes, including OCT4, NANOG,
c-MYC, and SOX2, and promoted self-renewal properties [58,154]. Similar results were
also observed in kidney and fibroblast human cell lines [155].
EpCAM is not typically expressed in normal hepatocytes, but EpCAM expression
has been observed in embryonic liver tissue and in regenerative stem cells of the adult
liver [156]. In hepatocellular carcinoma (HCC), EpCAM is considered a CSC marker [157]
and EpCAM positive HCC cell lines were shown to have increased proliferative properties
compared to EpCAM negative cells [158]. Tumor associated macrophages and hepatic
stellate cells are part of the tumor micro-environment and support HCC development. Both
cell types have been shown to stimulate EpCAM expression, EMT/stemness characteristics,
proliferation, and migration. This was mediated, in part, through TGB-β1 signaling,
a prominent inducer of EMT [159,160]. EpCAM is frequently co-expressed with EMT
and stemness markers in human HCC specimens and positive EpCAM expression has
been associated with a worse prognosis [159,161]. EpCAM expression, however, has also
been shown to be negatively associated with other important CSC/EMT characteristics in
HCC, including chemotherapy and molecular therapy resistance [158,162]. Thus, it seems
that EpCAM expression may be necessary to promote and maintain some CSC and EMT
properties, but is unnecessary for other features.
EpCAM is expressed in fetal pancreatic tissue [163] and EpCAM+/CD24+/CD44+
pancreatic adenocarcinoma cells were identified as CSCs with potent tumorigenic poten-
tial [164]. Notably, these CSCs also expressed epithelial (E-cadherin) and mesenchymal
(N-cadherin, Vimentin, and SNAI2) markers. Inhibition of Notch signaling (a mediator of
CSCs) in EpCAM+/CD44+ pancreatic CSCs decreased EpCAM and mesenchymal marker
expression, and also had inhibitory effects on in vitro and in vivo growth [165].
11. EpCAM and Drug Resistance during EMT
Chemotherapy treatment and molecular therapies frequently affect EMT, stemness
characteristics, and EpCAM expression. Cisplatin treatment of primary human ovarian
cancer cells and the ovarian cancer cell line OVCA 433 induced EMT and CSC marker
overexpression, which also included increased EpCAM expression. The observed changes
were controlled, in part, by ERK2 signaling, but it was not specifically tested whether
changes in EpCAM expression were caused by ERK2 signaling [166]. Another study that
analyzed CTCs in ovarian cancer patients similarly showed that chemotherapy induced
EMT changes, but EpCAM expression decreased in tested CTCs [167]. In breast cancer, loss
of EpCAM expression in CTCs served as a marker of chemotherapy resistance [146], while
another study showed increased EpCAM expression in treatment resistant patients [168].
12. Future Directions
Crystal structural analysis has demonstrated that the second motif of EpCAM between
amino acids 63 and 135 resembles a type 1 thyroglobulin domain (TY-1) [25]. TY-1 domains
are present in many other proteins and can function as cathepsins-L (CTSL) inhibitors [169].
It has been hypothesized that EpCAM may be able to inhibit CTSL activity as well [1].
CTSL is highly expressed in many cancers [170,171], degrades extracellular matrix (ECM)
proteins, and promotes cancer cell invasion and metastases [172]. Preclinical studies
have demonstrated that CTSL targeting in cancer patients may be an effective therapeutic
strategy [173]. The ectodomain of EpCAM and CTSL are both secreted into the tumor micro-
environment of cancer patients [20,174–176], whereby EpCAM could possibly inhibit CTSL
activity. This would presumably have a negative effect on EMT progression, as the ability
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to degrade the ECM is a hallmark feature of EMT progression. We recently demonstrated
that the TY-1 domain of EpCAM can inhibit CTSL activity [177].
13. Conclusions
EpCAM has a complex and sometimes contradictory role during EMT and is an im-
portant area for future research. EpCAM is an epithelial marker and is expressed on
the basolateral membrane of normal epithelial cells, promotes cell adhesions, and plays
an important role in maintaining the epithelial integrity of the gastrointestinal tract. Ep-
CAM is downregulated with EMT and inhibits EMT in a double-negative feedback loop
that involves ERK signaling. EMT transcription factors frequently silence EpCAM expres-
sion. In head and neck cancers, EpEX stimulation of EGFR had negative effects on EMT
progression, though it promoted cell growth. Many studies have demonstrated that Ep-
CAM expression was inversely related to the expression of mesenchymal markers and EMT
transcription factors. Most mesenchymal tissues and cancers have minimal or no detectable
EpCAM expression, while high EpCAM expression is frequently present in epithelial can-
cers. Many cancer types lose EpCAM expression during tumor cell dissemination with
EMT and/or dedifferentiation.
As outlined above, EpCAM may be able to promote EMT by negatively regulating
epithelial junctional protein complex formations. This occurs, in part, through direct
interactions with junctional proteins and possibly through indirect signaling mechanisms.
EpICD functions as a nuclear signaling molecule and promotes EMT progression through β-
catenin pathway activation. Many studies have shown that EpCAM and EpICD expression
promotes cancer cell migration and invasion, a phenotype typically associated with EMT.
Analysis of human tumor samples demonstrate that nuclear EpICD expression is associated
with more aggressive cancer behavior and decreased survival. EpCAM expressing CTCs
that also elaborate mesenchymal markers promote metastasis formation and serve as
a negative prognostic maker. EpCAM has been demonstrated in clinical studies to be
a promising target in the detection and treatment of metastatic epithelial cancers.
Thus, EpCAM demonstrates a dynamic and context dependent role during EMT and
cancer initiation and progression. Future research exploring EpCAM’s role in EMT may
reveal additional therapeutic opportunities in the diagnosis, treatment, and monitoring of
patients with epithelial cancers.
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ADAM17 ADAM metallopeptidase 17
AP-1 activator protein 1
ATC anaplastic thyroid cancer
BAA bead aggregation assays
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CAM cell adhesion molecule
CD carboxyl-terminal domain
CSC cancer stem cells
CTC circulating tumor cells
CTE congenital tufting enteropathy
CTSL cathepsins L
DTCs disseminated tumor cells
ECM extracellular matrix
EGFR epidermal growth factor receptor
ERK extracellular signal-regulated kinases
EpCAM epithelial cell adhesion molecular
EpEX EpCAM extracellular domain
EpICD EpCAM intracellular domain
FHL2 four-and-a-half LIM domains 2
FILM-FRET fluorescence-lifetime imaging based Förster resonance energy transfer
EMT epithelial-to-mesenchymal transition




LEF1 lymphoid enhancer binder factor 1
MET mesenchymal-to-epithelial transition (MET)
MMPs matrix metallopeptidases
ND N-terminal domain
nPKC novel protein kinase C
OCT4 octamer-binding transcription factor 4
PDTC poorly differentiated thyroid cancer
PSEN2 presenilin 2
RIP regulated intramembrane proteolysis
shRNA short-hairpin RNA
SAXS small angle X-ray scattering
SP signal peptide
TACE tumor necrosis factor-α-converting enzyme
TCF4 transcription factor 4
TGF-β1 transforming growth factor- β1
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